Showing results (511-520 of 1,089) with videos related to
Sort By:
Pageof 109
European Journal of Clinical Investigation|October 10, 1998
Time course of immunological markers in patients with the systemic inflammatory response syndrome: evaluation of sCD14, sVCAM-1, sELAM-1, MIP-1 alpha and TGF-beta 2B Stoiser, S Knapp, F Thalhammer, et al.The Journal of Investigative Dermatology|March 1, 1990
Establishment of a human cutaneous T-cell lymphoma in C.B-17 SCID miceM R Charley, M Tharp, J Locker, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 8, 2001
Sequential administration of interferon-gamma, GM-CSF, and interleukin-2 in patients with metastatic renal cell carcinoma: results of a phase II trialM Schmidinger, G Steger, C Wenzel, et al.Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|June 8, 2001
Sequential Administration of Interferon-gamma, GM-CSF, and Interleukin-2 in Patients With Metastatic Renal Cell Carcinoma: Results of a Phase II TrialManuela Schmidinger, Guenther Steger, Catharina Wenzel, et al.Toxicologic Pathology|January 1, 1986
Immunogenetics of development and its relationship to carcinogenesisT J Gill, H W Kunz, M Melhem, et al.Anesthesiology|December 25, 2004
Evaluation of Seldinger technique emergency cricothyroidotomy versus standard surgical cricothyroidotomy in 200 cadaversNikolaus Schaumann, Veit Lorenz, Peter Schellongowski, et al.Anti-Cancer Drugs|June 3, 2005
Darbepoetin alpha as treatment for anemia in patients receiving chemotherapy: a single-center experienceRupert Bartsch, Catharina Wenzel, Ursula Sevelda, et al.Public Health Nutrition|July 7, 2011
Sociodemographic, health and lifestyle predictors of poor dietsJanas Harrington, Anthony P Fitzgerald, Richard Layte, et al.Oncogene|February 1, 1996
BCR gene recombines with genomically distinct sites on band 11Q13 in complex BCR-ABL translocations of chronic myeloid leukemiaC Morris, A Jeffs, T Smith, et al.Oncogene|May 16, 1996
p21 contains independent binding sites for cyclin and cdk2: both sites are required to inhibit cdk2 kinase activityR Fotedar, P Fitzgerald, T Rousselle, et al.Pageof 109